Therefore, we used Western blotting to examine phosphorylated levels of MEK1/2 and ERK1/2, MEK1/2, ERK1/2, LC3B, and BNIP3 in shCANX-GBM#P3 cells after treatment with the MEK agonist C16-PAF and in CANX-overexpressing U118-MG cells following treatment with the MEK inhibitor PD9805. The gene discussed is MAP2K1; the disease is glioblastoma.